Compare ENVA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENVA | NUVB |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.9B |
| IPO Year | 2011 | N/A |
| Metric | ENVA | NUVB |
|---|---|---|
| Price | $137.66 | $4.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $173.00 | $11.22 |
| AVG Volume (30 Days) | 258.5K | ★ 4.8M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.05 | N/A |
| EPS | ★ 11.52 | N/A |
| Revenue | ★ $3,151,653,000.00 | N/A |
| Revenue This Year | $149.91 | $182.76 |
| Revenue Next Year | $15.38 | $91.83 |
| P/E Ratio | $12.35 | ★ N/A |
| Revenue Growth | ★ 18.58 | N/A |
| 52 Week Low | $79.41 | $1.57 |
| 52 Week High | $176.68 | $9.75 |
| Indicator | ENVA | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 33.85 |
| Support Level | $135.44 | $3.92 |
| Resistance Level | $149.49 | $5.73 |
| Average True Range (ATR) | 5.98 | 0.35 |
| MACD | -0.36 | -0.07 |
| Stochastic Oscillator | 17.98 | 25.27 |
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.